Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.44 |
| ▸ | YAP1 | P46937 | 2/20 | 0.44 |
| ▸ | REN | P00797 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10168522 | 0.92 | ACE (0.47) | ACEATML3MBTL1MMP1MMP3 | |
| SCHEMBL2755697 | 0.92 | ATM (0.54) | ACEATML3MBTL1GAAALDH1A1 | |
| SCHEMBL20530134 | 0.90 | YAP1 (0.51) | ACEATML3MBTL1KLK5YAP1 | |
| SCHEMBL18811643 | 0.90 | YAP1 (0.51) | ACEATML3MBTL1KLK5YAP1 | |
| SCHEMBL14956963 | 0.90 | YAP1 (0.51) | ACEATML3MBTL1KLK5YAP1 | |
| SCHEMBL19394007 | 0.90 | YAP1 (0.51) | ACEATML3MBTL1KLK5YAP1 | |
| SCHEMBL20530136 | 0.90 | YAP1 (0.51) | ACEATML3MBTL1KLK5YAP1 | |
| SCHEMBL20530135 | 0.90 | YAP1 (0.51) | ACEATML3MBTL1KLK5YAP1 | |
| SCHEMBL2755704 | 0.89 | ALDH1A1 (0.52) | ACEATML3MBTL1ALDH1A1HSD17B10 | |
| SCHEMBL3267848 | 0.88 | ACE (0.46) | ACEATML3MBTL1KLK5CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703714-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703714-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120027783-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027783-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120003247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120003247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-7994135-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994135-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7745394-B2 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745394-B2 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | ACE 3491/4885ATM 3298/4885L3MBTL1 824/4885 |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | MMAB, CAD, TRIM59 | ACE 3066/4885ATM 3697/4885L3MBTL1 260/4885 |
| US-20120027783-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | ACE 3491/4885ATM 3298/4885L3MBTL1 824/4885 |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | ACE 3395/4885ATM 3168/4885L3MBTL1 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.